warning: call_user_func_array() [function.call-user-func-array]: First argument is expected to be a valid callback, 'bowobs_menu_bowob_access' was given in /home/wepicks1/public_html/includes/menu.inc on line 452.

BioTech

Eli Lilly Earns Major Win As Appeals Court Upholds Evista Ban (LLY, TEVA)

BioTech Investor - BioTech Stock News - 1 September 2010 - 12:43pm
According to Reuters, Eli Lilly & Co. (NYSE: LLY) won a major battle against Teva Pharmaceutical Industries Limited (NASDAQ: TEVA), which had been petitioning for a generic version of Lilly’s drug, Evista. The court upheld the patent on Evista, which is used to treat Osteoporosis. -Michael B. Sauter

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Inhibitex Completes Trial For Hep C Drug

BioTech Investor - BioTech Stock News - 1 September 2010 - 12:16pm
Inhibitex Inc. (NASDAQ: INHX) was up $0.16 (11.27%) this morning to $1.58 on news that the company had completed a Phase1a, single ascending dose trial of its nucleotide polymerase inhibitor, INX-189.  The drug is currently being developed for the treatment of chronic hepatitis C.  Tests of the drug have, at this point, been positive with [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Intendis Enters Deal With Kythera For Fat-Reduction Drug

BioTech Investor - BioTech Stock News - 1 September 2010 - 11:53am
Intendis, Bayer Healthcare’s dermatology sector, has signed a deal with Los Angeles-based biopharma company Kythera Biopharmaceuticals in which the company receives rights to Kythera’s lead product candidate, ATX-101, in areas outside of the United States and Canada.  Kythera, in return, will receive $43 million upfront and up to $330 million beyond their initial payment.  ATX-101 is used [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Pluristem Placental Cells Found Effective For Several Treatments

BioTech Investor - BioTech Stock News - 30 August 2010 - 11:37am
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is up 12.87% this morning after it announced that its PLX therapeutic stem cell line, derived from the material of a human placenta, would be the only type of cell selected for a study designed to prevent inflammatory heart disease, also called diastolic heart failure. Shares of PSTI is up [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

AVEO Discovers Potential Cancer Breakthrough

BioTech Investor - BioTech Stock News - 30 August 2010 - 11:03am
AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) was up $0.75 (9.14%) this morning to $8.96 following reports that by introducing an experimental drug during chemotherapy the company had succeeded to wipe out brain cancer cells in mice.  This news provides hope for a new treatment for the disease in humans, and testing in humans has already begun. [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Sanofi-Aventis Forcibly Rejected In Genzyme Bid

BioTech Investor - BioTech Stock News - 30 August 2010 - 10:55am
For the past several months, rumors and reports have flown about French pharmaceutical behemoth Sanofi-Aventis (NYSE: SNY) devoting heavy resources to acquiring American research company Genzyme Corporation (NASDAQ: GENZ). The firms have gone back and forth on offers since early last month. Today, the Genzyme rejected Sanofi’s latest effort. Genzyme CEO explained his company’s actions, [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Roche Cancer Drug Does Not Receive FDA Approval

BioTech Investor - BioTech Stock News - 30 August 2010 - 10:48am
Swiss drugmaker Roche took a blow this past Friday after the U.S. FDA denied the company’s request for accelerated approval regarding trastuzumab-DM1, or T-DM1.  The drug, according to Reuters, “comprises ImmunoGen’s DM1 cancer-cell-killing agent linked to the HER2-targeting antibody trastuzumab, or Herceptin,” as a means of combating cancer.  The FDA’s decision will now setback the [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

GSK Gets Boost As Shingles Vaccine Enters Late Stage. AGEN Goes Along For Ride. (GSK, AGEN)

BioTech Investor - BioTech Stock News - 26 August 2010 - 1:42pm
GlaxoSmithKline’s (NYSE: GSK) new shingles recently entered phase III trials, and is expected to breeze through these as well. Meanwhile, Antigenics Inc. (NYSE: AGEN) the company responsible for the vaccine’s adjuvant, also experienced a major jump yesterday. Shares of GSK are up .56% today to $37.63. Shares of AGEN are down 3.68% to $0.82, but [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

DARA Biopharma Faces Delisting (DARA)

BioTech Investor - BioTech Stock News - 26 August 2010 - 11:36am
DARA Biosciences, inc. (NASDAQ: DARA) is on the chopping block after being notified by the SEC that the company didn’t meet the minimum equity requirement to continue to be publicly traded on the NASDAQ. The market’s minimum requirement is $2.5 million, and, according to the pharma company’s 10-Q report, it no longer meets that standard. [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Genzyme Faces Merger Bid From Sanofi

BioTech Investor - BioTech Stock News - 26 August 2010 - 10:04am
Sanofi-Aventis SA (NYSE: SNY) has raised it’s final offer for the purchase of Genzyme (NASDAQ: GENZ) to $70 a share, up one dollar from their initial offer of $69.  The price is certainly not one to thrill those at Genzyme, however insiders report that Sanofi holds concerns over manufacturing setbacks at the company. “Sanofi doesn’t [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Prana Biotechnology Secures Crucial Patents In Europe and the U.S.

BioTech Investor - BioTech Stock News - 25 August 2010 - 3:50pm
Prana Biotechnology (NASDAQ: PRAN) is up 8.77% a half hour before close after announcing this morning that it had secured several key patent extensions from the United States Patents and Trademark Office (USPTO) and the European Patent Office (EPO). The company recieved received up to 2.5-year extensions for its PBT2 line, which has been used [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

The Worm Turns in Genzyme-Sanofi Deal (GENZ, SNY)

BioTech Investor - BioTech Stock News - 25 August 2010 - 12:59pm
We have cautioned about the value of Genzyme Corporation (NASDAQ: GENZ) if Sanofi-Aventis (NYSE: SNY) either doesn’t raise a bid or if it walks away.  The wild card is that Genzyme is taking its sweet time and it could be pushing Sanofi away. We have heard and read that the implied original offer around $69 [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Somaxon Teams With Procter & Gamble Regarding New Drug

BioTech Investor - BioTech Stock News - 25 August 2010 - 10:40am
Somaxon Pharmaceuticals Inc. (NASDAQ: SOMX) jumped $1.39 (41.25%) to $4.76 today on news that the biopharma company had signed a deal with Procter & Gamble to market the company’s new insomnia drug, Silenor.  In return for helping Somaxon sell the drug, which is a low-dose from of doxepin, P & G will gain first rights [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Stem Cell Breakthrough Offers Possible Treatments For Baldness and More

BioTech Investor - BioTech Stock News - 24 August 2010 - 4:00pm
In a recent breakthrough for stem cell technology, Swiss and Scottish scientists at the University of Lausanne in Switzerland discovered that when stem cells from the thymus were transplanted into the developing skin of rats, new follice cells, capable of hair-growth, were created.  These cells are more potent than normal hair follicle stem cells, supporting [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Streamline’s Audit Solution Picked Up By Children’s National

BioTech Investor - BioTech Stock News - 24 August 2010 - 3:19pm
Streamline Health Solutions Inc. (NASDAQ: STRM) was up $0.12 (11.76%) today to $1.14 on news that the company’s Audit Compliance for the Enterprise Solution had been implemented at Children’s National in Washington, DC.  The audit solution was introduced by Streamline earlier this year, and officials at Children’s Nation report that they have already benefited from [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

FDA Shoots Down Jazz Pharmaceuticals’ Fibromyalgia Treatment

BioTech Investor - BioTech Stock News - 24 August 2010 - 12:12pm
Jazz Pharmaceuticals (NASDAQ: JAZZ) lost one of its development-stage drugs today when an FDA panel vetoed JZP-6, which was designed to treat Fibromyalgia, a painful nervous disorder. According to Reuters, one of the main reasons for the denial was the presence of hydroxybutyrate (GHB) which is known colloquially as “the date rape drug.” The panel [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

The Case Grows Against All That Jazz (JAZZ)

BioTech Investor - BioTech Stock News - 23 August 2010 - 3:40pm
Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ) is having an awful day, and frankly this is a situation that could have been even worse for holders considering the speculative phase that the company is in versus its existing portfolio. The FDA advisory committee voted against Jazz’s fibromyalgia candidate in a voted tallied at 20-2 against approval.  The [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Biodel Gains Despite Losses

BioTech Investor - BioTech Stock News - 23 August 2010 - 2:33pm
Biodel Inc. (NASDAQ: BIOD) was up $0.32 (7.73%) today to $4.46 despite recent reports of a Q3 net loss of $8.6 million, or $0.36 per share.  The company possessed shares valued at almost $20 in the summer of 2008, however investor interest has since waned considerably.  Possible FDA approval of the company’s device that device [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

EpiCept Concerns Growing Much Stronger (EPCT)

BioTech Investor - BioTech Stock News - 23 August 2010 - 12:17pm
EpiCept Inc. (NASDAQ: EPCT) may be facing an even less promising future as you might have guessed based on a $1.10 closing price with a $55 million market-cap on Friday.  Shares are getting butchered on Monday as a result of an FDA denial in acceptance of its new drug application for Ceplene which the company [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

EpiCept Concerns Growing Much Stronger (EPCT)

BioTech Investor - BioTech Stock News - 23 August 2010 - 12:17pm
EpiCept Inc. (NASDAQ: EPCT) may be facing an even less promising future as you might have guessed based on a $1.10 closing price with a $55 million market-cap on Friday.  Shares are getting butchered on Monday as a result of an FDA denial in acceptance of its new drug application for Ceplene which the company [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Latest Status Updates
cassiewardtl n/a 3 days ago
PENNYGURU n/a 1 week ago
Rhodegirl n/a 1 week ago
bhere » adminjosh n/a 5 weeks ago
majorherreraqn n/a 7 weeks ago
paddan n/a 8 weeks ago
paddan n/a 8 weeks ago
whh n/a 8 weeks ago
adminjosh n/a 19 weeks ago
pennybuilder n/a 19 weeks ago
adminjosh n/a 24 weeks ago
adminjosh n/a 26 weeks ago
adminjosh n/a 26 weeks ago
IncuStock n/a 28 weeks ago
adminjosh n/a 30 weeks ago
more
Syndicate content